For toxicologists and safety pharmacologists, in vitro data offer an early warning of clinical hazards. How can we extract the most actionable intelligence from these data? The answer is three-fold: by making the interpretation of risk evidence-based, consistent across projects, and a routine part of the design-make-test-analyze cycle.
Watch our to webinar to learn how scientists can detect and interpret risks from pharmacological profiling as a part of lead optimization. We’ll explain how off-target activity, direction of modulation, projected unbound exposure, and clinical precedents all inform the prediction of clinical risk at the point of discovery.
We’ll also share how to embed risk stratification into the DMTA cycle, so teams can prioritize compounds more intelligently, guide chemistry away from liabilities, and reserve in vivo studies for candidates with the highest chance of success.
Key Learning Objectives:
- How to contextualize secondary pharmacology data for safety insight
- How to benchmark off-target risk against clinical precedents
- How to stratify safety risk early and pragmatically
- How early safety insight can reduce downstream attrition
This webinar is ideal for:
- Head of Research and Development
- Head of Data Innovation
- Medicinal chemists
- Safety pharmacologists
- 毒理学家
- Biologists
演讲嘉宾：
- David Lowis, DPhil
- Will Redfern, PhD
